Immix Biopharma (IMMX) Long-Term Deferred Tax (2022 - 2026)

Immix Biopharma (IMMX) posted Long-Term Deferred Tax of $164723.0 for Q1 2026, up 75.93% sequentially from $93630.0 in Q4 2025.

Immix Biopharma (IMMX) Long-Term Deferred Tax (2022 - 2026) Analysis & Trends

Immix Biopharma has reported Long-Term Deferred Tax for 4 years, with the latest figure at $164723.0 in Q1 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $164723.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164723.0 (changed N/A YoY) and the FY2025 annual result came in at $93630.0, changed N/A from the prior year.
Long-Term Deferred Tax climbed to $164723.0 in Q1 2026 per IMMX's latest filing, from $93630.0 in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $164723.0 in Q1 2026 and troughed at $6724.0 in Q4 2022.
A 4-year average of $95766.8 and a median of $102118.0 in 2025 frame the typical range for Long-Term Deferred Tax.
The widest YoY moves for Long-Term Deferred Tax: up 1197.28% in 2023, down 1197.28% in 2023.
Over 4 years, Long-Term Deferred Tax stood at $6724.0 in 2022, then surged by 1197.28% to $87229.0 in 2023, then climbed by 7.34% to $93630.0 in 2025, then soared by 75.93% to $164723.0 in 2026.
According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $164723.0, $93630.0, and $111689.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Immix Biopharma	784.75 Mn	784.75 Mn	-

Download Data